Tag: revascularization procedures in coronary artery disease

Meta-analysis Muses Over ISCHEMIA Message Had Trial Lasted Longer

Would the ISCHEMIA trial be quite the compass for conservative care it now is in stable coronary artery disease (CAD) if follow-up for the primary...

New Light Cast on Type-2 MI Aims to Sharpen Diagnosis, Therapy

The hospital and post-discharge course of patients diagnosed with type-2 myocardial infarction (MI), triggered when myocardial oxygen demand outstrips supply, differs in telling ways from...

Ischemia Not Linked to 10-Year Mortality, CABG Benefit

The presence of ischemia on stress testing should not be used to refer patients with ischemic cardiomyopathy for coronary artery bypass graft (CABG) surgery, a...

Once Again, No Survival Benefit With PCI, Surgery in Stable CAD

Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according...

Icosapent Ethyl Cuts Revascularization: Latest From REDUCE-IT

A new analysis from the REDUCE-IT trial has shown that the high-strength eicosapentaenoic acid product icosapent ethyl (Vascepa, Amarin) reduced the number of revascularization procedures...

CABG Bests PCI in Evidence-Poor Arena of Systolic Dysfunction

A new matched-cohort analysis may fill some gaps in the evidence base that guides coronary revascularization strategy in patients with poor ventricular systolic function, who...

Radial Arteries Show CABG Survival Advantage Over Saphenous Veins

Coronary bypass surgery patients who received a radial artery as their second bypass conduit had significantly better 10-year survival than did patients who received a...

Unusually Long-Term PCI vs CABG Data in LMCA

It is a truth universally acknowledged that a trial comparing interventional strategies for left-main coronary artery (LMCA) disease launched more than a decade ago may...

CV Benefit Directly Related to EPA Levels

The reduction in cardiovascular (CV) events seen in the REDUCE-IT trial with icosapent ethyl (Vascepa, Amarin), a high-strength formulation of purified eicosapentaenoic acid (EPA), were...